Insilico Medicine reports 40% ORR at 130 mg for Pan-TEAD inhibitor ISM6331 designed using generative AI in heavily pretreated mesothelioma at ESMO 2026
ESMO 2026: New targeted therapy improved survival for patients with KRAS-mutated lung cancer
ESMO 2026: UT MD Anderson highlights innovative approaches to monitor, prevent and treat cancer
ESMO 2026: Immunotherapy combination extends survival in advanced endometrial cancer
ESMO: New analysis reinforces survival benefits of targeted therapy for advanced pancreatic cancer
Gustave Roussy at the ESMO 2026 Congress
Insilico Medicine to present first-in-human data for AI-designed pan-TEAD inhibitor ISM6331 at ESMO 2026
ESMO launches funding program for academic studies aimed at optimizing cancer care pathways
ESMO launches funding program for academic studies aimed at optimizing cancer care pathways
Insilico Medicine announces oral presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in mesothelioma and advanced solid tumors - EurekAlert!
ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma - EurekAlert!
ESMO: 10-year survival data for lung cancer immunotherapy, new PSMA-targeted therapy for recurrent prostate cancer, promising results in metastatic colorectal and urothelial cancers - EurekAlert!
